SLC5A2 and chronic kidney disease: Within the ADA Standards of Care, agents with ‘proven benefit’ are operationally defined as those with an expanded indication for improving ASCVD, HF or CKD outcomes (Table 4).16,18,64,65 Based on observed HF benefits in patients with and without T2D, the 2022 heart failure guidelines from the American Heart Association/ American College of Cardiology/Heart Failure Society of America recommend SGLT2 inhibitors within their treatment algorithm to improve HF outcomes.66